Compare SMID & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMID | MDXH |
|---|---|---|
| Founded | 1960 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Building Materials | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.2M | 183.4M |
| IPO Year | 1996 | 2021 |
| Metric | SMID | MDXH |
|---|---|---|
| Price | $34.25 | $3.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 4.0K | ★ 112.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 866.67 | N/A |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $78,508,000.00 | N/A |
| Revenue This Year | N/A | $30.31 |
| Revenue Next Year | N/A | $18.38 |
| P/E Ratio | $18.04 | ★ N/A |
| Revenue Growth | ★ 31.77 | N/A |
| 52 Week Low | $25.16 | $1.36 |
| 52 Week High | $43.62 | $5.33 |
| Indicator | SMID | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 43.62 | 41.26 |
| Support Level | $33.59 | $3.05 |
| Resistance Level | $37.90 | $3.78 |
| Average True Range (ATR) | 1.47 | 0.18 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 27.63 | 11.32 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.